000 05516nam a22006015i 4500
001 978-3-030-44903-2
003 DE-He213
005 20211012165741.0
007 cr nn 008mamaa
008 200427s2020 sz | s |||| 0|eng d
020 _a9783030449032
_9978-3-030-44903-2
024 7 _a10.1007/978-3-030-44903-2
_2doi
050 4 _aQH529
050 4 _aQH491-492
072 7 _aPSC
_2bicssc
072 7 _aSCI072000
_2bisacsh
072 7 _aPSC
_2thema
082 0 4 _a571.8
_223
245 1 0 _aSenolytics in Disease, Ageing and Longevity
_h[electronic resource] /
_cedited by Daniel Muñoz-Espin, Marco Demaria.
250 _a1st ed. 2020.
264 1 _aCham :
_bSpringer International Publishing :
_bImprint: Springer,
_c2020.
300 _aX, 222 p. 21 illus., 16 illus. in color.
_bonline resource.
336 _atext
_btxt
_2rdacontent
337 _acomputer
_bc
_2rdamedia
338 _aonline resource
_bcr
_2rdacarrier
347 _atext file
_bPDF
_2rda
490 1 _aHealthy Ageing and Longevity,
_x2199-9015 ;
_v11
505 0 _aPart I: Origins and Development of Senotherapies -- Chapter 1. Senolytic drug development -- Chapter 2. Discovery of Senolytics and the pathway to early phase clinical trials -- Part II: The Impact of Senotherapies: from Regeneration to Aging -- Chapter 3. Interconnection between cellular senescence, regeneration and ageing in salamanders -- Chapter 4. Senolytics target senescent cells and improve aging and age-related diseases -- Chapter 5. Senotherapy of cancer -- Part III: Understanding and Targeting the Senescent Surfaceome -- Chapter 6. Targeted senolytic strategies based on the senescent surfaceome -- Chapter 7. Senolysis and senostasis through the plasma membrane -- Part IV: Novel Senescence-Associated Markers and Targets -- Chapter 8. In situ detection of miRNAs in senescent cells in archival material -- Chapter 9. Novel probes and carriers to target senescent cells -- Chapter 10. Potential applications of aptamers for targeting senescent cells -- Chapter 11. Mitochondria: potential targets for interventions to counteract senescence.
520 _aThis book offers comprehensive information on the new and rapidly evolving science of identifying and targeting senescent cells, and on the exciting prospect of new diagnostic and therapeutic opportunities for stopping, and even reversing, the progression of disease and the deterioration of the human body due to ageing. According to recent United Nations data, by 2050 one in six people worldwide will be older than age 65, with peaks rising to one in four people in Europe and North America. Remarkably, the number of persons aged 80 years or older is expected to triple, from 143 million in 2019 to 426 million in 2050. First documented in the 1960s, the concept of cellular senescence as an underlying cause of ageing has been established in the course of the last decade. Using genetically engineered mouse models, researchers have demonstrated that the selective elimination of senescent cells can block and even reverse a number of age-related dysfunctions and pathologies, promoting both better health and longer life in the elderly. These include cardiovascular diseases; neurological disorders; type 1 and type 2 diabetes; inflammatory diseases; fibrosis; geriatric syndromes; chronic diseases resulting in organ dysfunction; the integrity of the musculoskeletal system; and cancer. Some senolytic agents have already progressed into trials. These include UBX0101 for the treatment of osteoarthritis (now in phase II), a cocktail of dasatinib and quercetin for the management of idiopathic pulmonary fibrosis and chronic kidney disease, and ABT-263 in combination with senescence-inducing chemotherapies for the treatment of advanced solid tumours. In addition, the book discusses pathways to early phase clinical trials and translational approaches in medicine and ageing, highlighting new opportunities as well as current limitations, challenges and alternatives. Given its scope, it will benefit a broad audience of advanced educators, researchers, graduate students and practitioners.
650 0 _aAging.
650 0 _aDevelopmental biology.
650 0 _aRegenerative medicine.
650 0 _aTissue engineering.
650 0 _aAnimal models in research.
650 0 _aMolecular biology.
650 1 4 _aBiogerontology.
_0https://scigraph.springernature.com/ontologies/product-market-codes/B25000
650 2 4 _aRegenerative Medicine/Tissue Engineering.
_0https://scigraph.springernature.com/ontologies/product-market-codes/L16080
650 2 4 _aAnimal Models.
_0https://scigraph.springernature.com/ontologies/product-market-codes/L25050
650 2 4 _aMolecular Medicine.
_0https://scigraph.springernature.com/ontologies/product-market-codes/B1700X
700 1 _aMuñoz-Espin, Daniel.
_eeditor.
_4edt
_4http://id.loc.gov/vocabulary/relators/edt
700 1 _aDemaria, Marco.
_eeditor.
_4edt
_4http://id.loc.gov/vocabulary/relators/edt
710 2 _aSpringerLink (Online service)
773 0 _tSpringer Nature eBook
776 0 8 _iPrinted edition:
_z9783030449025
776 0 8 _iPrinted edition:
_z9783030449049
776 0 8 _iPrinted edition:
_z9783030449056
830 0 _aHealthy Ageing and Longevity,
_x2199-9015 ;
_v11
856 4 0 _uhttps://doi.org/10.1007/978-3-030-44903-2
912 _aZDB-2-SBL
912 _aZDB-2-SXB
950 _aBiomedical and Life Sciences (SpringerNature-11642)
950 _aBiomedical and Life Sciences (R0) (SpringerNature-43708)
999 _c548260
_d548195